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ABSTRACT
Introduction: Brazilian epidemiological studies on rheumatoid arthritis are scarce, thus all data currently available originate 
from the international literature. Objectives: To determine the incidence and some clinical and laboratory characteristics of 
patients with rheumatoid arthritis in the municipality of Cascavel, state of Paraná, Brazil. Patients and methods: Data were 
collected between August 2010 and July 2011 in all health services of the municipality of Cascavel that provided health care 
in Rheumatology: a university-af¿ liated hospital, a public outpatient clinic and four private clinics. Results: We identi¿ ed 
38 patients diagnosed with rheumatoid arthritis, resulting in an estimated incidence of 13.4 cases per 100,000 inhabitants/
year. Thirty two patients were females, whose mean age was 47.6 years. The age group with the highest incidence was 
over 40 years. The mean time between ¿ rst symptoms and diagnosis was 12.4 months. Rheumatoid factor was positive in 
68.4% of the patients, and 18.4% already had radiological abnormalities at diagnosis. The pharmacological treatment of 
patients was also assessed and proved to be in accordance with those found in the literature. Conclusion: The incidence 
of rheumatoid arthritis obtained in the municipality of Cascavel was lower than those reported in international studies.
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INTRODUCTION
Rheumatoid arthritis (RA) is a systemic chronic inÀ amma-
tory disease of autoimmune character and unknown etiology, 
which affects large and small joints symmetrically. It is more 
prevalent in women (female/male ratio of 2:1), and its inci-
dence increases with age.1 
Rheumatoid arthritis affects approximately 0.5%–1% of 
the population, and, although not directly life-threatening, it 
causes a reduction in the patient’s quality of life and severe 
economic damages to society.2 
The incidence of RA varies according to the popula-
tion and geographic area studied. Most epidemiological 
studies have been conducted in developed countries, while 
reports on the incidence of RA in developing countries 
have been rare. Studies have shown a lower prevalence of 
RA in developing countries as compared with developed 
countries.3 
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This study aimed at assessing the incidence of RA in a 
Brazilian municipality and describing the clinical and laboratory 
characteristics of patients with RA.
PATIENTS AND METHODS
This study comprised the review of the medical records of 
patients diagnosed with RA in the municipality of Cascavel, 
state of Paraná (PR), Brazil, from August 2010 to July 2011. 
All rheumatology services of that municipality took part in 
this study as follows: a university-af¿ liated hospital of Western 
Paraná (Hospital Universitário do Oeste do Paraná – HUOP); the 
regional center of specialties of the intermunicipal health con-
sortium of Western Paraná (Centro Regional de Especialidades 
do Consórcio Intermunicipal de Saúde do Oeste do Paraná – 
CRE-CISOP); and four private rheumatology clinics. 
Data were collected through active search in the medical 
records of patients whose diagnosis of RA had been con¿ rmed 
by a rheumatologist. Data were recorded in a speci¿ c spread-
sheet, constructed and validated to minimize differences in 
data recording across different services. The following data 
were assessed: gender; age range; time from the ¿ rst complaint 
until RA diagnosis; clinical and laboratory manifestations; 
and drug therapy. Clinical and laboratory data were assessed 
regarding their compliance with the 1987 American College of 
Rheumatology (ACR) criteria.4 The new  2010 ACR-EULAR 
criteria were not used, because they had not been published by 
the beginning of this study.
This study’s exclusion criteria were as follows: 1) patients 
diagnosed with RA not living in the municipality of Cascavel; 2) 
residents of the municipality of Cascavel diagnosed with RA by a 
rheumatologist, but who did not meet the minimum ACR criteria. 
The municipality of Cascavel is located in the Western region 
of the state of Paraná, in the Southern region of Brazil. In 2010, 
its population was 283,193 inhabitants (146,434 women and 
139,771 men), according to data from the Brazilian Institute of 
Geography and Statistics (IBGE).5 Those ¿ gures were used to 
calculate the incidence of RA. The municipality of Cascavel is 
a regional pole of health care in the state of Paraná, providing 
health services in different medical specialties to the so-called 
Western macro-region, which comprises 25 municipalities 
and has approximately 470,000 inhabitants. It is not a speci¿ c 
pole for the treatment of RA, but offers specialized health care 
in private clinics and at the Brazilian Public Uni¿ ed Health 
Care System (SUS), through the CRE-CISOP and the HUOP 
outpatient clinic. 
Data were presented as frequencies, medians, and means ± 
standard deviations, with 95% con¿ dence interval (CI).
This study was approved by the Committee of Ethics and 
Research (nº 239-2010) of the Western Paraná State University 
(UNIOESTE), and its authors declare no conÀ ict of interest.
RESULTS
This study identi¿ ed 38 patients diagnosed with RA and living in 
the municipality of Cascavel. The incidence of cases of RA at the 
services assessed was 13.42 cases per 100,000 inhabitants/year. 
Of the 38 patients, 32 were females and 6, males. The incidence 
for the female gender was 21.9/100,000 inhabitants/year, and 
for the male gender, 4.3/100,000 inhabitants/year, resulting in 
female/male ratio of 5.3:1.
The mean age at the time of diagnosis was 47.6 ± 16.7 years 
(95% CI: 42.2–53.0), ranging from 17 to 76 years (median of 
38 years). The mean time between the appearance of the ¿ rst 
symptoms and disease diagnosis was 12.4 ± 12.6 months (95% 
CI: 7.8–17.0), ranging from 1 month to 60 months (median of 
9 months). Table 1 shows the incidence and frequency of RA 
per age group.
In this study, the compliance with the 1987 ACR criteria 
for the diagnosis of RA was as follows: 22 patients met 4 of the 
7 criteria; 12 patients met 5 criteria; 2 patients met 6 criteria; 
and 1 patient met 7 criteria. The most frequently met criterion 
was that of radiographic changes, observed in 7 patients, 6 of 
whom were of the female gender. Table 2 shows the clinical 
and laboratory manifestations comprising the ACR diagnostic 
criteria detected in the patients.
When diagnosed with RA, the patients also underwent the 
following laboratory tests: C-reactive protein (CRP) and eryth-
rocyte sedimentation rate (ESR). Those measurements were 
elevated in 31 (81.6%) and 26 (68.4%) patients, respectively.
Table 1
Frequency of cases and incidence of rheumatoid arthritis 
according to the age group of patients diagnosed at 
rheumatology services in the municipality of Cascavel, PR, 
Brazil, in 2010–2011
Age group 
(years) n
Frequency of 
cases (%) Population
Incidence/
100,000 
inhabitants
< 20 1 2.7 91,964 1.09
20–29 7 18.9 53,969 12.97
30–39 3 8.1 46,545 6.45
40–49 9 24.3 40,217 22.38
50–59 8 21.6 27,795 28.78
60–69 5 13.5 15,294 32.69
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Compared with international indices, the incidence of 
RA found in the municipality of Cascavel (13.4/100,000 
inhabitants/year) is lower than those of Northern Europe and 
the USA,8 which ranged from 20 and 50 cases per 100,000 
inhabitants/year. The incidence of RA found in the municipal-
ity of Cascavel is closer to those found in Southern Europe (9 
to 24 cases per 100,000 inhabitants/year).7,3 One reason for 
that might be the climate similarity between those countries 
and Southern Brazil (temperate climate).7,9 Table 5 lists the 
incidence data. 
Studies on the incidence of RA in Brazil lack, hindering 
comparisons with other Brazilian places; however, data on 
the prevalence of RA in Brazil show lower indices than those 
reported in other places worldwide.6,10,11
In addition to the variations in methodology and criteria 
between studies, another explanation for the lower prevalence 
and incidence of RA found in developing countries might be 
the lower degree of urbanization of those countries and the 
greater dif¿ culty patients face in reaching health care centers 
in developing countries.12 
Data from the Norfolk Arthritis Register have shown inci-
dences of RA for the female and male genders of 54/100,000 
inhabitants/year and 24.5/100,000 inhabitants/year, respec-
tively, evidencing an approximately twice greater incidence 
of RA in the female gender.13 Those data are similar to those 
reported by Symmons et al.14 in another European study. 
The female/male ratio in the municipality of Cascavel was 
higher than that found in developed countries, although the 
incidences for both men and women were smaller. That dif-
ference in the incidences in our study might be related to the 
Table 2
Clinical and laboratory manifestations comprised in the ACR 
diagnostic criteria detected in the patients studied
ACR criteria n (%)
Edema in at least 3 joints 38 (100%)
Edema in hand joints 38 (100%)
Symmetrical edema 35 (92.1%)
Rheumatoid factor 26 (68.4%)
Morning stiffness 15 (39.5%)
Radiological changes 7 (18.4%)
Subcutaneous nodules 5 (13.2%)
ACR = American College of Rheumatology.
Table 3
Drug treatment prescribed for patients diagnosed with 
rheumatoid arthritis in the municipality of Cascavel, PR, Brazil
Drug n (%)
Methotrexate 31 (81.6%)
Prednisone 27 (71.1%)
Non-steroidal anti-inﬂ ammatory drugs 17 (44.7%)
Hydroxychloroquine 6 (15.8%)
Sulfasalazine 1 (2.6%)
Table 4
Drug associations prescribed for patients diagnosed with 
rheumatoid arthritis in the municipality of Cascavel, PR, Brazil
Drug n (%)
MTX + hydroxychloroquine 4 (10.5%)
MTX + leﬂ unomide 1 (2.6%)
MTX + sulfasalazine 1 (2.6%)
MTX + cyclophosphamide 1 (2.6%)
Prednisone + NSAIDs 15 (39.5%)
MTX = methotrexate; NSAIDs = non-steroidal anti-inﬂ ammatory drugs.
Table 5
Comparison of the incidence of rheumatoid arthritis in the 
municipality of Cascavel, PR, Brazil, with international data 
(cases/100,000 inhabitants)
Author, study site Time period Total of RA cases (n)
Incidence 
(per 100,000 
inhabitants)
Present study, 
municipality of 
Cascavel (Brazil)
2010–2011 38 13.4
Doran et al.,17 
Rochester (USA) 1985–1994 147 32.7
Carbonell et al.,18 
Spain 2004–2005 362 8.3
Kaipiainen-
Seppanen et al.,24 Finland 1985 413 39
Pedersen et al.,25 
Southern Denmark 1995–2001 505 35
Drosos et al.,26 Greece 1987–1995 428 20
Table 3 shows the speci¿ c drugs for RA used to treat the 
patients. Disease-modifying anti-rheumatic drugs (DMARDs) 
and non-steroidal anti-inÀ ammatory drugs (NSAIDs) listed in 
Table 3 were used in combination for some patients. Table 4 
shows such combinations. 
DISCUSSION
Epidemiological studies on RA are mostly limited to devel-
oped countries,3,6 the incidence of RA in developing countries 
being unknown.3,6–8
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cultural attitude of the Brazilian male to search medical care 
only in the presence of symptoms, in addition to the dif¿ culty 
in accessing health care services.15 Another Brazilian study 
has also reported a markedly high female/male ratio.10
The mean age found in this study coincides with that 
reported in the literature for the peak incidence of RA, that 
is, after the fourth decade of life.1 Brazilian and international 
studies have reported similar age groups.16,17
Considering the RA classi¿ cation criteria, our study’s 
data suggest lower positivity for the criterion ‘presence or 
absence of subcutaneous nodules’ as compared with the study 
carried out in the state of São Paulo in 200716 (18% and 29%, 
respectively). This might be explained by the fact that the 
study from the state of São Paulo assesses prevalence, con-
sidering both new and old cases, while ours considered only 
the new cases, in which the characteristics of RA have not 
developed in its full severity. A French study,17 involving 14 
rheumatology centers in the period from 2002 to 2005, has 
assessed 579 patients meeting the 1987 ACR criteria for the 
diagnosis of RA and reported the following results: arthritis 
in at least 3 joints, 95.7%; symmetrical arthritis,  92.9%; and 
morning stiffness, 95%. Comparing with our study, except 
for morning stiffness, those values do not differ much (100%, 
92.1% and 39.5%, respectively), which might be explained 
by the fact of it being a study on prevalence.
Regarding positivity for the rheumatoid factor, our data 
are very similar to those of two other Brazilian studies (68.4% 
in the municipality of Cascavel, 71% in the municipality of 
São Paulo,15 and 63% in the municipality of Montes Claros10), 
although the other Brazilian studies were on prevalence. 
However, comparing with studies on incidence, the pres-
ence of the rheumatoid factor is greater than that reported in 
international studies.18,19 
The immediate beginning of treatment is important to 
reduce disease activity and prevent lesions that can gener-
ate functional disabilities. That treatment can be as follows: 
non-medicamentous; symptomatic; and with DMARDs. The 
symptomatic treatment should be performed with NSAIDs, 
and, when necessary, prednisone can be associated. If pred-
nisone is used for a long time, calcium and vitamin D should 
be associated to prevent bone damage.20 Only 17 patients 
(44.7%) were on NSAIDs during the period studied. That is 
in accordance with the literature, which recommends the use 
of NSAIDs at lower doses and for the shortest time possible 
to avoid complications. If the treatment with NSAIDs is 
not effective to control pain, therapy with DMARDs should 
be considered.20 Of the 17 patients on NSAIDs, 2 were on 
monotherapy, because they had mild symptoms of the disease. 
The most common adverse effects in patients on NSAIDs 
are gastrointestinal symptoms,20 explaining the large number 
of patients on a proton-pump inhibitor for gastric protection. 
In our study, omeprazole was used by 10 patients (26.3%).
In our study, 27 patients (71.1%) were on glucocorticoids, 
which are mainly used to control the exacerbations of the 
disease for both new and old cases.
Regarding DMARDs, 25 of 38 patients (65.8%) diagnosed 
with RA in the period studied and undergoing treatment, used 
methotrexate (MTX) in monotherapy. MTX is recommended 
for all patients diagnosed with RA, regardless of disease 
duration. It is considered the standard drug for the treatment 
of RA, because it is the best tolerated.20–22 In addition, 2 
patients (5.3%) used hydroxychloroquine in monotherapy. 
That drug is recommended for those who do not have a poor 
prognosis and whose disease activity is low. Drug treatment 
can also involve associations of 2 or more DMARDs. The 
best association is MTX and hydroxychloroquine, indicated 
for patients with moderate disease activity,21 and used for 
4 patients (10.5%) in our study. Other associations recom-
mended are MTX with leÀ unomide, for patients with long 
disease duration and low disease activity, and MTX with 
sulfasalazine, for patients with high disease activity and 
worse prognosis.22 In our study, each of those associations 
was used by 1 patient (2.6%).
The importance of studying the epidemiology of RA is 
based on the need of assessing the impact of that disease on 
the population health and also intended to help with the calcu-
lation and priorities of organizing health care.23 Nevertheless, 
studies on the incidence of RA face some dif¿ culties, such 
as establishing the point at which the disease actually starts, 
de¿ ning which criterion should be used for diagnosis, and the 
delay between symptom onset and medical care, which can 
falsely reduce the estimates on the incidence of that disease.8,23
New criteria have been de¿ ned by the 2010 ACR-EULAR 
to help with the early diagnosis of RA.8 That might improve 
studies on incidence, because many rheumatologists identify 
and treat patients with RA based on their professional experi-
ence, even if the patient does not meet the 1987 ACR criteria.23
Further studies involving other Brazilian regions should 
be carried out to establish whether that is a characteristic 
¿ nding of the Brazilian population or only an isolated ¿ nding.
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Faz-se necessário desenvolver  mais estudos envolvendo 
outras regiões para estabelecer se este resultado é um achado 
característico da população do país ou somente um achado 
isolado.
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